Eli Lilly has sent cease-and-desist letters to U.S. healthcare providers in recent days to stop the promotion of the compounded versions of its drugs for weight loss and diabetes, as their supply ...

Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, Mounjaro and Zepbound, after the FDA declares the tirzepatide shortage ...

OrderlyMeds, a provider of compounded versions of GLP-1 weight loss drugs, including Eli Lilly’s (NYSE:LLY) tirzepatide, said on Friday that a cease-and-desist letter sent by the pharma giant ...

Eli Lilly has sent cease-and-desist letters to hundreds of compounding pharmacies, telehealth companies, and medical spas making and selling “compounded” versions of tirzepatide.

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ingredient in its popular weight-loss and diabetes medicines.

Several months after a group of senators sent letters to Pfizer and Eli Lilly investigating their respective direct-to-consumer telehealth platforms, the lawmakers are now directing similar ...

On Tuesday, a group of senators sent letters to five telehealth companies that offer care through direct-to-consumer portals from pharmaceutical manufacturers Pfizer and Eli Lilly, interrogating ...

Eli Lilly And Co. (NYSE:LLY) is ramping up its legal campaign against the compounding companies temporarily allowed to make and sell copycat versions of its blockbuster drugs for weight loss until ...